- Nurix to work with Roche on BTK degrader in pact worth up to $2.3BRoche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...Endpoints · 1mo ago↗ source
- Innovation alone is no longer enough in biopharma<p>In biopharma, the next edge may come from the systems that turn discovery into scale.</p>BioPharma Dive · 1mo ago↗ source
- Precision under pressure: Logistic solutions for nuclear medicine scalability<p>Racing the clock: How precision logistics deliver life-saving nuclear medicine.</p>BioPharma Dive · 1mo ago↗ source